MIRA-1是一种马来酰亚胺类化合物，能够恢复突变型p53的野生型构象及功能。
Cas No.:72835-26-8
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
MIRA-1 is a maleimide-type compound with the ability to restore wild type conformation and function to mutant p53 [1]. MIRA-1 can reactivate and restore apoptosis-promoting activity to mutant p53 (at residues R175H and R273H) by increasing DNA fragmentation and inducing caspase activity [2]. MIRA-1 has been widely used in cell and animal models to inhibit tumor progression[3].
In vitro, MIRA-1 treatment for 48 hours significantly inhibited the growth of Saos-2-His273 cells, with an IC50 value of 10μM[4]. Treatment with 10μM MIRA-1 for 48 hours significantly induced apoptosis in LP1 cells, inhibited cell migration, and led to the upregulation of Puma and Bax expression, while downregulating Mcl-1 and c-Myc expression[5]. Treatment with 25μM MIRA-1 for 2 hours induces apoptosis in human normal fibroblasts, accompanied by cell shrinkage and an irregular star-shaped morphology[6]. Treatment with 2μM MIRA-1 for 3 days significantly inhibited the survival of HeLa cells, resulting in impaired DNA synthesis ability of the cells and delayed progression of the S phase[7]. Treatment with 3μM MIRA-1 for 48 hours notably promoted cell cycle arrest in C8166 cells, resulting in a decrease in the expression of cell cycle protein D1[8].
In vivo, MIRA-1 (1mg/kg) was administered intraperitoneally daily for 10 consecutive days, which significantly inhibited tumor growth in mice with xenografted H1299-His175 cells[4]. For two consecutive weeks, intraperitoneal injection of MIRA-1 (10mg/kg) every other day significantly reduced the tumor burden in mice with xenograft tumors of 8226 cells and prolonged the survival time of the mice[5].
References:
[1] Silva J L, Lima C G S, Rangel L P, et al. Recent synthetic approaches towards small molecule reactivators of p53[J]. Biomolecules, 2020, 10(4): 635.
[2] Yu X, Narayanan S, Vazquez A, et al. Small molecule compounds targeting the p53 pathway: are we finally making progress?[J]. Apoptosis, 2014, 19(7): 1055-1068.
[3] Saha M N, Jiang H, Yang Y, et al. Small Molecule MIRA-1 Induces p53-Independent Apoptosis in Multiple Myeloma Cells Through Activation of the p38 MAPK Signaling Pathway[J]. Blood, 2012, 120(21): 2937.
[4] Bykov V J N, Issaeva N, Zache N, et al. Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs[J]. Journal of Biological Chemistry, 2005, 280(34): 30384-30391.
[5] Saha M N, Chen Y, Chen M H, et al. Small molecule MIRA-1 induces in vitro and in vivo anti-myeloma activity and synergizes with current anti-myeloma agents[J]. British journal of cancer, 2014, 110(9): 2224-2231.
[6] Bou-Hanna C, Jarry A, Lode L, et al. Acute cytotoxicity of MIRA-1/NSC19630, a mutant p53-reactivating small molecule, against human normal and cancer cells via a caspase-9-dependent apoptosis[J]. Cancer letters, 2015, 359(2): 211-217.
[7] Aggarwal M, Sommers J A, Shoemaker R H, et al. Inhibition of helicase activity by a small molecule impairs Werner syndrome helicase (WRN) function in the cellular response to DNA damage or replication stress[J]. Proceedings of the National Academy of Sciences, 2011, 108(4): 1525-1530.
[8] Moles R, Bai X T, Chaib-Mezrag H, et al. WRN-targeted therapy using inhibitors NSC 19630 and NSC 617145 induce apoptosis in HTLV-1-transformed adult T-cell leukemia cells[J]. Journal of hematology & oncology, 2016, 9(1): 121.
MIRA-1是一种马来酰亚胺类化合物，能够恢复突变型p53的野生型构象及功能[1]。MIRA-1可通过增加DNA片段化并诱导caspase活性，重新激活突变型p53（R175H和R273H位点）并恢复促凋亡活性[2]。MIRA-1已被广泛用于细胞和动物模型中以抑制肿瘤进展[3]。
在体外，MIRA-1处理48小时显著抑制了Saos-2-His273细胞的生长，IC50值为10µM[4]。使用10µM的MIRA-1处理48小时，显著诱导了LP1细胞凋亡，抑制了细胞迁移，并导致Puma和Bax表达上调，同时Mcl-1和c-Myc表达下调[5]。使用25µM的MIRA-1处理2小时，诱导了人正常成纤维细胞凋亡，伴随细胞皱缩及不规则星形形态[6]。使用2µM的MIRA-1处理3天，显著抑制了HeLa细胞的存活，导致细胞DNA合成能力受损并延缓S期进程[7]。使用3µM的MIRA-1处理48小时，显著促进了C8166细胞发生周期阻滞，导致细胞周期蛋白D1表达下降[8]。
在体内，每日腹腔注射1mg/kg剂量的MIRA-1，连续10天，显著抑制了携带H1299-His175细胞异种移植瘤小鼠的肿瘤生长[4]。连续两周，每隔一天腹腔注射10mg/kg剂量的MIRA-1，显著减少了8226细胞异种移植瘤小鼠的肿瘤负荷，并延长了小鼠的存活时间[5]。
| Cell experiment [1]: | |
Cell lines | LP1 cells |
Preparation Method | LP1 cells were cultured in DMEM medium containing 10% fetal bovine serum (FBS), 2mM L-glutamine, 50U penicillin and 50µg/ml streptomycin at 37℃ in the presence of 5% CO2. LP1 cells (5×104 cells/well) were inoculated in 96-well cell culture plate and incubated at 37°C with 5% CO2 for 24h. Then, the cells were treated with 0μM, 5μM, 10μM, 15μM, and 20μM MIRA-1 for 48h, respectively, and cell viability was measured. |
Reaction Conditions | 0μM, 5μM, 10μM, 15μM, and 20μM; 48h |
Applications | MIRA-1 treatment suppressed the cell viability of LP1 cells in a dose-dependent manner. |
| Animal experiment [2]: | |
Animal models | SCID mice |
Preparation Method | SCID mice were housed in a temperature-controlled (22±1°C) room maintained on a 12/12h light/dark cycle. All mice were adaptively fed for one week. Freshly harvested H1299-His175 cells (5×106 cells per mouse, resuspended in 100μl PBS) were injected into the armpit of the mice. The mice were given 1mg/kg MIRA-1, or PBS i.p. once daily for 10 days. Body weights were measured every other day. On the 34th day, all mice were killed, and the tumor was segregated and weighed. |
Dosage form | 1mg/kg/day for 10 days; i.p. |
Applications | MIRA-1 treatment inhibited tumor growth in a xenograft model of H1299-His175 cells without affecting body weight. |
References: | |
| Cas No. | 72835-26-8 | SDF | |
| 别名 | NSC 19630 | ||
| 化学名 | 1-[(1-oxopropoxy)methyl]-1H-pyrrole-2,5-dione | ||
| Canonical SMILES | CCC(=O)OCN1C(=O)C=CC1=O | ||
| 分子式 | C8H9NO4 | 分子量 | 183.16 |
| 溶解度 | 18.3mg/mL in ethanol, or in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 5.4597 mL | 27.2985 mL | 54.5971 mL |
| 5 mM | 1.0919 mL | 5.4597 mL | 10.9194 mL |
| 10 mM | 546 μL | 2.7299 mL | 5.4597 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet